sub:assertion {
  d:DB00262 dv:ddi-interactor-in dr:DB00262_DB01656 .
  d:DB01656 dv:ddi-interactor-in dr:DB00262_DB01656 .
  dr:DB00262_DB01656 dct:identifier "drugbank_resource:DB00262_DB01656" ;
    dct:title "DDI between Carmustine and Roflumilast - Roflumilast may enhance the immunosuppressive effect of immunosuppressants such as carmustine. The Canadian roflumilast product monograph recommends avoiding concurrent use of roflumilast with any immunosuppressant medications due to the antiinflammatory/immune altering effects of roflumilast and the lack of relevant clinical experience with such use. Of note, this recommendation to avoid concurrent use does not apply to either inhaled corticosteroids (which have much more limited systemic immune-suppressing actions) or short-term systemic corticosteroid use. U.S. prescribing information does not contain this warning; but it appears prudent to avoid this combination when possible."@en ;
    a dv:Drug-Drug-Interaction ;
    rdfs:label "DDI between Carmustine and Roflumilast - Roflumilast may enhance the immunosuppressive effect of immunosuppressants such as carmustine. The Canadian roflumilast product monograph recommends avoiding concurrent use of roflumilast with any immunosuppressant medications due to the antiinflammatory/immune altering effects of roflumilast and the lack of relevant clinical experience with such use. Of note, this recommendation to avoid concurrent use does not apply to either inhaled corticosteroids (which have much more limited systemic immune-suppressing actions) or short-term systemic corticosteroid use. U.S. prescribing information does not contain this warning; but it appears prudent to avoid this combination when possible.  [drugbank_resource:DB00262_DB01656]"@en .
}